Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
February 20, 2026 15:10 ET | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British…
U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the…
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB),…
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position…
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:…
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical…
Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million
Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private…
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:…
ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx),…
